Kangmei Pharmaceutical Co Ltd (SHG:600518) — Market Cap & Net Worth
Market Cap & Net Worth: Kangmei Pharmaceutical Co Ltd (600518)
Kangmei Pharmaceutical Co Ltd (SHG:600518) has a market capitalization of $3.46 Billion (CN¥23.65 Billion) as of May 2, 2026. Listed on the SHG stock exchange, this China-based company holds position #4533 globally and #815 in its home market, demonstrating a -1.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kangmei Pharmaceutical Co Ltd's stock price CN¥1.71 by its total outstanding shares 13828896690 (13.83 Billion). Analyse how efficiently does Kangmei Pharmaceutical Co Ltd generate cash to see how efficiently the company converts income to cash.
Kangmei Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Kangmei Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $32.97 Billion to $3.46 Billion (-18.91% CAGR).
Index Memberships
Kangmei Pharmaceutical Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$4.18 Trillion | 0.08% | #171 of 285 |
Weight: Kangmei Pharmaceutical Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kangmei Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kangmei Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.91x
Kangmei Pharmaceutical Co Ltd's market cap is 0.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
552.30x
Kangmei Pharmaceutical Co Ltd's market cap is 552.30 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $32.97 Billion | $18.07 Billion | $2.76 Billion | 1.82x | 11.96x |
| 2016 | $35.18 Billion | $21.64 Billion | $3.34 Billion | 1.63x | 10.53x |
| 2017 | $44.48 Billion | $17.58 Billion | $2.15 Billion | 2.53x | 20.69x |
| 2018 | $18.51 Billion | $17.07 Billion | $374.49 Million | 1.08x | 49.44x |
| 2019 | $7.55 Billion | $11.45 Billion | -$4.66 Billion | 0.66x | N/A |
| 2020 | $5.42 Billion | $5.41 Billion | -$31.08 Billion | 1.00x | N/A |
| 2021 | $6.25 Billion | $4.15 Billion | $7.92 Billion | 1.51x | 0.79x |
| 2022 | $4.45 Billion | $4.18 Billion | -$2.69 Billion | 1.07x | N/A |
| 2023 | $3.76 Billion | $4.87 Billion | $102.52 Million | 0.77x | 36.71x |
| 2024 | $4.74 Billion | $5.19 Billion | $8.57 Million | 0.91x | 552.30x |
Competitor Companies of 600518 by Market Capitalization
Companies near Kangmei Pharmaceutical Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Kangmei Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Kangmei Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Kangmei Pharmaceutical Co Ltd's market cap moved from $32.97 Billion to $ 3.46 Billion, with a yearly change of -18.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.46 Billion | -10.47% |
| 2025 | CN¥3.87 Billion | -18.38% |
| 2024 | CN¥4.74 Billion | +25.81% |
| 2023 | CN¥3.76 Billion | -15.45% |
| 2022 | CN¥4.45 Billion | -28.80% |
| 2021 | CN¥6.25 Billion | +15.30% |
| 2020 | CN¥5.42 Billion | -28.15% |
| 2019 | CN¥7.55 Billion | -59.23% |
| 2018 | CN¥18.51 Billion | -58.38% |
| 2017 | CN¥44.48 Billion | +26.45% |
| 2016 | CN¥35.18 Billion | +6.70% |
| 2015 | CN¥32.97 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Kangmei Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.46 Billion USD |
| MoneyControl | $3.46 Billion USD |
| MarketWatch | $3.46 Billion USD |
| marketcap.company | $3.46 Billion USD |
| Reuters | $3.46 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kangmei Pharmaceutical Co Ltd
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical … Read more